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Abstract
Background: Previous studies have reported conflicting results for the comparative doses of recombinant follicle
stimulating hormone (rFSH) and highly purified human menopausal gonadotrophin (hMG-HP) required per cycle of
in vitro fertilisation (IVF); the aim of this study was to determine the average total usage of rFSH versus hMG-HP in
a ‘real-world’ setting using routine clinical practice.
Methods: This retrospective chart review of databases from four European countries investigated gonadotrophin
usage, oocyte and embryo yield, and pregnancy outcomes in IVF cycles (± intra-cytoplasmic sperm injection) using
rFSH or hMG-HP alone. Included patients met the National Institute for Health and Clinical Excellence (NICE)
guideline criteria for IVF and received either rFSH or hMG-HP. Statistical tests were conducted at 5% significance
using Chi-square or t-tests.
Results: Of 30,630 IVF cycles included in this review, 74% used rFSH and 26% used hMG-HP. A significantly lower
drug usage per cycle for rFSH than hMG-HP (2072.53 +/- 76.73 IU vs. 2540.14 +/- 883.08 IU, 22.6% higher for hMG-
HP; p < 0.01) was demonstrated. The median starting dose was also significantly lower for rFSH than for hMG-HP
(150 IU vs. 225 IU, 50% higher for hMG-HP, p < 0.01). The average oocyte yield per IVF cycle in patients treated
with rFSH was significantly greater than with hMG-HP (10.80 +/- 6.02 vs. 9.77 +/- 5.53; p < 0.01), as was the
average mature oocyte yield (8.58 +/- 5.27 vs. 7.72 +/- 4.59; p < 0.01). No significant differences were observed in
pregnancy outcomes including spontaneous abortion between the two treatments. There was a significantly
higher rate of OHSS (all grades) with rFSH (18.92% vs. 14.09%; p < 0.0001). The hospitalisation rate due to OHSS
was low but significantly higher in the rFSH group (1.07% of cycles started vs. 0.67% of cycles started with rFSH
and hMG-HP, respectively; p = 0.002).
Conclusions: Based on these results, IVF treatment cycles with rFSH yield statistically more oocytes (and more
mature oocytes), using significantly less IU per cycle, versus hMG-HP. The incidence of all OHSS and hospitalisations
due to OHSS was significantly higher in the rFSH cycles compared to the hMG-HP cycles. However, the absolute
incidence of hospitalisations due to OHSS was similar to that reported previously. These results suggest that the
perceived required dosage with rFSH is currently over-estimated, and the higher unit cost of rFSH may be offset by
a lower required dosage compared with hMG-HP.
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The prevalence of infertility has increased over the past
20-30 years, in part due to the rise in obesity levels [1] and
a decline in male fecundity and poor semen quality [2] but
also due to couples choosing to have children later in life
[3]. The reported prevalence of infertility in Europe varies
significantly between studies, and there is a paucity of reli-
able data. A recent review of international infertility rates
reported the current median prevalence of infertility to be
9% over 12 months among women aged 20-44 in married
and consensual unions [4]. The proportion of infertile
couples seeking infertility treatment in more developed
countries ranged from 42-76% [4]. A recent report from
the Human Fertilisation and Embryology Authority
(HFEA) states that in the year 2007, 36,861 women in the
United Kingdom (UK) received 46,829 cycles of IVF treat-
ment; a 5.8% increase from 2006 [5].
In conventional in vitro fertilisation (IVF) treatment,
gonadotrophins are administered in order to stimulate
an ovarian cycle. Follicle stimulating hormone (FSH) is
universally recognised as the key driver of ovarian folli-
cle growth and maturation, and is most often adminis-
tered in one of two forms: recombinant FSH (rFSH;
Gonal-F® (Merck Serono) or Puregon® (Merck Sharp
and Dohme)) or highly purified human menopausal
gonadotrophin (hMG-HP; Menopur® (Ferring) or Merio-
nal® (Pharmasure)) which contains both FSH and lutei-
nising hormone (LH) activity in a ratio of 1:1.
The comparative clinical efficacy of rFSH and hMG
and/or hMG-HP has been investigated previously. A
Cochrane review published in 2003 [6] concluded that
there was insufficient evidence to establish a difference
between hMG and rFSH on ongoing pregnancy rate or
live birth rate for ovulation stimulation in IVF or ICSI
cycles. More recent meta-analyses have included the
results from more recent studies including the MERIT
study group [7]; a large randomised controlled trial
( R C T )t h a tc o m p a r e dh M G - H Pw i t hr F S Hi np a t i e n t s
undergoing IVF/ICSI. Two of these meta-analyses, which
evaluated the comparative efficacy of rFSH and hMG
(both of which included hMG-HP and hMG) for ovarian
stimulation in IVF or ICSI cycles, reported a higher rate
of clinical pregnancy and live birth rate for hMG than
rFSH [8,9]. An additional meta-analysis (which included
hMG-HP only) [10], concluded that there was no statisti-
cal difference between rFSH and hMG-HP in ongoing
and live birth rates in a combined group of IVF and ICSI;
however, subset analysis showed a statistically significant
higher ongoing pregnancy/live birth rate in favour of
hMG-HP in IVF cycles. This study also reported the total
dose (International Units, IU) of gonadotrophins used
and the average number of oocytes retrieved; there was
significant statistical heterogeneity between trials, but
sensitivity analyses suggested that there was no signifi-
cant difference in these measurements between
treatments.
There is a perception that the cost per IVF cycle with
rFSH is more expensive compared with the Menopur®
brand of hMG-HP, as the 75 IU equivalent of Gonal-F®
rFSH has a higher unit cost than the corresponding price
for Menopur®. It is unclear whether the same dose (total
IU dose) of rFSH and hMG-HP is required per IVF cycle;
however, several studies suggest that this may not be the
case. While meta-analyses by Coomarasamy et al [9]
(which included hMG as well as hMG-HP) and a recent
study by Al Inany et al (2009) (which included hMG-HP
only) [10] showed no significant difference in IU require-
ment between the products, an earlier meta-analysis by
Al-Inany et al (2008) [8] (which included both hMG and
hMG-HP), did show a reduced IU requirement for rFSH
compared with hMG/hMG-HP.I na d d i t i o nt ot h i s ,t h e
recent large MERIT randomised controlled trial (RCT)
[7] has reported a reduced IU requirement per cycle for
rFSH versus hMG-HP.
The total dose of gonadotrophin per IVF cycle and its
associated cost may be a factor in determining which
gonadotrophin clinicians and payers choose to use in their
clinic. Therefore, it is important to understand the com-
parative dosing when establishing the relative costs of two
different treatments. Two studies have reported the com-
parative cost per IVF cycle using fresh embryo transfer
with rFSH and hMG-HP [11,12] and both conclude that
treatment per IVF cycle with hMG-HP is ultimately less
costly than treatment with rFSH (based on fresh embryo
transfer). In these studies, both rFSH and hMG-HP were
administered at the same starting dose (IU) and titrated
according to treatment outcomes. If it is true that a lower
than anticipated mean IU dosage of rFSH is required to
achieve comparable outcomes to hMG-HP, it can be
hypothesized that the net cost of treatment with rFSH
may be comparable or lower.
The objective of this study was to determine the aver-
age total IU usage in IVF cycles using rFSH alone versus
those utilising hMG-HP alone in combination with long
protocol GnRH agonist for pituitary down-regulation.
This large retrospective chart review from four European
countries provides an insight into the use of gonadotro-
phins in the ‘real-world’ clinic setting, as opposed to the
data gathered from RCTs which are limited by protocol-
driven treatment regimens and often may not reflect
‘real-world’ clinical practice. In the absence of European
consensus guidelines for IVF treatment, the data included
in this review were selected in a strict and robust method
according to the patients’ eligibility for IVF treatment as
defined by the current NICE guidelines [13]. NICE are a
globally recognised organisation for guideline production
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consulted and adopted by other countries in the absence
of local guidelines. This study did not focus on the costs
of comparative treatments, or the economic implications
of the results; therefore, no cost data are reported here.
Methods
Study design
This study was an observational retrospective chart review
of anonymised patient records from female patients who
have received rFSH or hMG-HP for IVF (±ICSI) in either
cycles 1, 2 or 3, across centres in Spain, Germany,
Denmark and Switzerland. Anonymised data relating to
gonadotrophin usage (type and amount administered),
oocytes retrieved, embryos transferred, embryos cryopre-
served, the occurrence of ovarian hyperstimulation syn-
drome (OHSS) and pregnancy outcomes were collected
retrospectively from clinic records, for all eligible patients
undergoing treatment. The severity of OHSS is classified
according to three grades of severity: mild, moderate and
severe, as defined by the World Health Organisation
(WHO) [14]. OHSS is classified according to the degree of
abdominal distension, ovarian enlargement, and respira-
tory, haemodynamic, and metabolic complications. Only
cycles from patients who would be eligible for treatment
under the current National Institute for Health and Clini-
cal Excellence (NICE) guidelines [13] were selected.
Eligible cycles were extracted from raw data sets pro-
vided by four European countries. To be eligible for
inclusion in the review, the cycles must have met the
following criteria:
Cycles that were:
(i) 1st, 2nd or 3rd IVF (±ICSI) cycles in women aged
23-39 years at the start of treatment with a body mass
index (BMI) of ≥19 and ≤29.
(ii) In women who have received a single form of FSH
only in a given cycle.
(iii) In women who have received rFSH only (Gonal-F®
or Puregon®) or hMG-HP only (Menopur® or Merional®)
at a starting dose of ≤300 IU FSH/day.
(iv) Cycles with long protocol, subcutaneous, GnRH
agonist down-regulation.
(v) In indications labelled in the Summary of Product
Characteristics (SPC) for the product.
(vi) Administered in 2004 or later with gonadotrophin
treatment for ≤25 days per cycle.
Cycles were excluded if:
(i) The patient has had 3 or more previously stimu-
lated, unsuccessful cycles of IVF (± ICSI).
(ii) The patient was ≥40 years old at the start of
treatment.
(iii) Down-regulation protocol was not long protocol,
subcutaneous GnRH agonist.
(iv) More than one FSH-containing product was used
in a single cycle.
(v) Follicle stimulation was achieved with a combination
of FSH and another adjunctive ovary stimulating product.
(vi) The starting dose of gonadotrophin was >300 IU
per day in order to exclude poor responders.
(vii) The indication was not licensed in the SPC for
the product.
(vii) Treatment was performed prior to 2004 (2004
was used as a cut off date, as cycles prior to 2004 may
include non-highly purified HMG).
(xi) The number of treatment days was >25.
Study endpoints
The primary endpoint of the study was the average IU
usage of rFSH versus hMG-HP per IVF cycle, utilizing
long protocol GnRH agonist for pituitary down-
regulation. The mean and median starting dose of each
gonadotrophin was also determined. Secondary clinical
endpoints included (i) oocyte yield (ii) mature oocyte
yield (iii) the average number of oocytes/embryos frozen
per cycle, following IVF treatment with rFSH versus
hMG-HP. Tertiary endpoints included the number of
IVF cycles resulting in (i) clinical pregnancy (ii) ongoing
pregnancy (iii) spontaneous abortion.
The main safety endpoints of the study include (i) the
rate of ovarian hyperstimulation syndrome (OHSS), (ii)
rate of OHSS resulting in hospitalisation (iii) IVF cycle
withdrawals.
In addition to the overall analysis, cycles were also
stratified according to the patient’sa g ea tt h et i m eo f
IVF treatment (≤35 years and ≥36 years).
Analysis of the raw data
An algorithm was developed which extracted for further
analysis those treatment cycles meeting the inclusion/
exclusion criteria. The algorithm consisted of nine steps
(Figure 1) and was validated using two different meth-
ods. Firstly, the algorithm extracted data that compared
to the results of hand-triaged Spanish data. Individual
cycles in the raw Spanish data set were examined indivi-
dually and only those cycles which fulfilled the entry cri-
teria were extracted for further analysis. This step led to
refinements of the algorithm. In addition, each step of
the algorithm was run separately to examine which data
were included and excluded and the findings were
cross-checked to ensure that the algorithm includes or
excludes relevant cycles.
Statistical analysis
Distributions of categorical variables were described in
terms of the number and proportion of cycles in each
level of the variable. For continuous data variables, the
Trew et al. Reproductive Biology and Endocrinology 2010, 8:137
http://www.rbej.com/content/8/1/137
Page 3 of 10results were presented as the mean, standard deviation,
median and range of values.
With regard to the association between IU per cycle
and outcome variables the approach depended on
whether the outcome was categorical (has at least one
procedure during the study period), or continuous (has
a number of procedures during the study period). For
categorical variables, the outcome was cross-tabulated
by sub-groups of interest, to describe the proportion in
each level having the outcome and tested using a Chi-
square test. For continuous variables, the distribution
of the values of the outcome was described for sub-
groups of interest. If the outcome variable had a nor-
mal distribution, a t-test or ANOVA was used to test
the association. If the distribution of the outcome vari-
able was skewed, a log-transformation was applied to
correct the distribution. If this failed, non-parametric
tests like the Mann-Whitney or Wilcoxon (Kruskal-
Wallis) tests were applied.
All statistical tests were conducted at 5% level of sig-
nificance. Unless otherwise stated statistical tests were
two-sided. Analyses were carried out using SAS software
version 9.1 (SAS Institute Inc, North Carolina, USA).
Results
Baseline
Following triage of the raw data using the algorithm, a
total of 30,630 IVF cycles (35.6% of the total cycles)
were eligible for inclusion in the review, 74% of which
involved treatment with rFSH and 26% with hMG-HP.
Demographics and baseline characteristics are shown in
Table 1. Although there was a statistically significant
difference in patient age between treatment groups (p <
0.01), the difference in age was 0.15 years (and the
mean patient age was 32.93 years) and therefore it was
not deemed to be clinically significant. Of the cycles
included in the analysis, 20,564 cycles were conducted
in patients ≤35 years and 10,066 were conducted in
patients ≥36 years (67% and 33% of cycles, respectively).
All patients included in the study were <40 years of age.
The vast majority of the chart data (>90%) was from
centres in Germany (Table 2); however, data from all
Figure 1 Algorithm flow process.
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the analysis.
Mean usage and duration of treatment with rFSH
versus hMG-HP
The mean total number of IU of rFSH used per cycle of
IVF (± ICSI) treatment was significantly lower than that
for hMG-HP (2072.53 ± 768.73 IU vs. 2540.14 ± 883.08
IU, p < 0.01) (Table 3). The mean usage of hMG-HP
w a s2 2 . 6 %g r e a t e rt h a nt h a tf o rr F S H .I na d d i t i o nt o
this, the mean length of gonadotrophin treatment per
IVF cycle was significantly shorter with rFSH than
hMG-HP (11.41 ± 2.24 days vs. 11.65 ± 2.42 days, p <
0.01), but this difference is not clinically relevant. The
mean starting dose of treatment was significantly lower
for rFSH than for hMG-HP for all patients (176.38 ±
50.01 IU vs. 206.16 ± 55.64 IU, p < 0.01), as was the
more clinically relevant median starting dose (150 IU vs.
225 IU, p < 0.01) (Table 3). Significant differences in the
primary outcomes were also observed when the data
were stratified according to patient age at time of treat-
ment (Table 3).
Mean oocyte yield after treatment with rFSH versus hMG-
HP
A statistically significant higher proportion of hMG-HP
cycles resulted in oocyte retrieval compared with rFSH
cycles (99.13% for rFSH vs. 99.91% for hMG-HP; p <
0.0001) (Table 4); however, it should be noted that the
German dataset did not include cycles where no oocytes
were retrieved. The mean oocyte yield per IVF cycle in
patients treated with rFSH was significantly greater than
in patients treated with hMG-HP (10.80 ± 6.02 vs. 9.77
± 5.53; p < 0.01), with an increase of 10.5% seen for
rFSH (equivalent to one extra oocyte per cycle on
average). The mean mature oocyte yield was also signifi-
cantly higher for rFSH than hMG-HP (8.58 ± 5.27 vs.
7.72 ± 4.59; p < 0.01) with an 11.1% increase in yield
with rFSH, but this difference is not clinically signifi-
cant. The mean oocyte yield and mean mature oocyte
yield were significantly higher for patients treated with
rFSH in both the ≤35 years and ≥36 years age subgroups
(Table 4).
The mean number of oocytes or embryos frozen per
IVF cycle was significantly higher in rFSH-treated
patients than patients treated with hMG-HP (2.14 ±
3.29 vs. 1.70 ± 2.80; p < 0.01) (Table 4).
The number of IVF cycles cancelled due to inadequate
response was only reported in the Swiss dataset, and
was approximately 10%.
Pregnancy outcomes
No significant differences were observed in the mean
clinical pregnancy rate as percent of cycles with oocytes
retrieved (rFSH 33.04% vs. 32.04% for hMG-HP; p =
0.1037). In addition, the mean rate of pregnancies ending
in spontaneous abortion as a percentage of cycles where
oocytes were retrieved, were comparable between the
two treatment groups (6.16% vs. 6.02% for rFSH and
hMG-HP, respectively; p = 0.6625) (Table 5 and Table 6).
A tt h et i m eo fd a t ac o l l e c t i o n ,3 , 1 9 4l i v eb i r t h sh a d
occurred in rFSH treated patients versus 1,228 live
births in the hMG-HP treated group (15.86% versus
15.51% of cycles started, respectively). The multiple
pregnancy rates were also comparable; 30.8% versus
25.9% with rFSH and hMG-HP, respectively. Any com-
parison between the two treatment groups for multiple
pregnancy rate is irrelevant as it does not take into
account the number of embryos transferred. The overall
multiple pregnancy rate was 29.4%.
Safety outcomes
The absolute number of cycles ending in OHSS (severity
I, II, III and hospitalisation) differed significantly between
treatments, with 18.92% of rFSH cycles ending in OHSS,
compared to 14.09% of hMG-HP cycles (p < 0.0001),
although due to limits on the data available the OHSS
data were based solely on the German dataset. There was
no significant difference between treatments in the mean
rate of hospitalisations due to OHSS (5.64% versus 4.75%
Table 1 Baseline characteristics
Characteristic rFSH hMG-HP All Patients
Number of cycles
All patients N (%) 22665 (74%) 7965 (26%) 30630
≤35 years N (%) 15422 (75%) 5142 (25%) 20564
≥36 years N (%) 7243 (72%) 2823 (28%) 10066
Age Mean (SD) 32.89 (3.57) 33.04 (3.71)
1,2 32.93 (3.61)
1 p < 0.01 in Wilcoxon two sample test
2 p < 0.01 in two sample t-test.
Table 2 IVF cycles according to country
Characteristic rFSH % hMG-HP % All Patients
Denmark N 1027 97.5 26 2.5 1053 (3.4% of total)
Germany N 20144 71.78 7919 28.22 28063 (91.6% of total)
Spain N 485 99.8 1 0.2 486 (1.6% of total)
Switzerland N 1009 98.15 19 1.85 1028 (3.4% of total)
Total number of cycles N 22665 74.0 7965 26.0 30630
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tively p = 0.2483) (Table 7). However, the mean propor-
tion of cycles with OHSS requiring hospitalisation as a
proportion of IVF cycles started was significantly higher
in the rFSH group (1.07% vs. 0.67%, p = 0.002).
Logistic regression was conducted retrospectively to
investigate the association between the rate of OHSS,
patient age, number of oocytes retrieved and type of
gonadotrophin used. Results of these analyses indicated
that younger age at treatment initiation and higher
number of oocytes produced are associated with a statis-
tically increased risk of OHSS and OHSS requiring hos-
pitalisation. Type of gonadotrophin used for oocyte
stimulation was not associated with a higher risk of
OHSS when the regression was adjusted for number of
oocytes retrieved.
Discussion
In today’s economic climate, treatment choices are made
not only on the basis of drug efficacy and safety; cost
considerations, driven in part by drug dosing, also play a
significant role. In this large retrospective European chart
review, it has been demonstrated that in IVF (±ICSI)
treatment cycles from eligible patients, cycles using rFSH
(as compared with hMG-HP) yield statistically more
oocytes and more mature oocytes, using significantly less
IU per cycle. The difference in mean IU usage per cycle
was 467.1 IU; a percentage reduction of 18.4%. Further-
more, the average number of oocytes/embryos frozen per
started IVF cycle was also statistically higher in rFSH
cycles compared with hMG-HP cycles. The clinical preg-
nancy and spontaneous abortion rates were comparable
between rFSH and hMG-HP treatment groups. Of the
Table 3 Primary outcomes
Characteristic rFSH hMG-HP p-value* All Patients
Mean (SD) total dose of gonadotrophin per IVF cycle (IU) (All patients) 2072.53 (768.73) 2540.14 (883.08) <0.01 2194.13 (825.9)
(≤35 years) 1974.90 (726.77) 2418.56 (834.46) <0.01 2085.84 (779.18)
(≥36 years) 2280.41 (813.09) 2761.60 (925.33) <0.01 2415.36 (873.21)
Mean (SD) total days of gonadotrophin treatment per IVF cycle (All patients) 11.41 (2.24) 11.65 (2.42) <0.01 11.47 (2.29)
(≤35 years) 11.41 (2.28) 11.65 (2.48) <0.01 11.47 (2.33)
(≥36 years) 11.41 (2.16) 11.65 (2.31) <0.01 11.48 (2.21)
Mean (SD) starting dose of gonadotrophin (IU) (All patients) 176.38 (50.01) 206.16 (55.64) <0.01 184.12 (53.16)
(≤35 years) 167.97 (46.65) 195.94 (53.48) <0.01 174.97 (49.94)
(≥36 years) 194.26 (52.18) 224.76 (54.67) <0.01 202.82 (54.63)
Median starting dose of gonadotrophin (IU) (All patients) 150 225 <0.01 150
(≤35 years) 150 225 <0.01 150
(≥36 years) 187.5 225 <0.01 225
* Statistical significance for all outcomes assessed via Wilcoxon two sample test and two sample T-test.
Table 4 Secondary outcomes
Characteristic rFSH hMG-HP p-value All Patients
Mean (SD)oocyte yield (number of oocytes retrieved) (All patients) 10.80 (6.02) 9.77 (5.53) <0.01 10.53 (5.91)
(≤35 years) 11.21 (6.11) 10.28 (5.6) <0.01 10.98 (6.0)
(≥36 years) 9.93 (5.74) 8.83 (5.27) <0.01 9.62 (5.63)
Mean (SD) mature oocyte yield (All Patients) 8.58 (5.27) 7.72 (4.59) <0.01 8.35 (5.11)
(≤35 years) 8.80 (5.35) 8.08 (4.66) <0.01 8.62 (5.19)
(≥36 years) 8.09 (5.06) 7.08 (4.38) <0.01 7.80 (4.9)
Number of embryos transferred (fresh) 1.91 (0.86) 1.96 (0.68) <0.01 1.93 (0.81)
(≤35 years) 1.89 (0.84) 1.94 (0.63) <0.01 1.91 (0.79)
(≥36 years) 1.96 (0.89) 2.00 (0.76) <0.01 1.97 (0.85)
Mean number of oocytes/embryos frozen per cycle All patients 2.14 (3.29) 1.7 (2.8) <0.01 2.02 (3.18)
(≤35 years) 2.32 (3.4) 1.8 (2.85) <0.01 2.18 (3.27)
(≥36 years) 1.77 (3.03) 1.51 (2.68) <0.01 1.70 (2.94)
Number of embryos thawed and used in FET** cycles† (All patients) 0.74 (0.97) 0.67 (0.93) <0.01 0.74 (0.97)
(≤35 years) 0.67 (0.95) 0.57 (0.9) <0.01 0.67 (0.94)
(≥36 years) 0.91 (1.03) 0.87 (0.99) <0.01 0.91 (1.02)
* Statistical significance for outcomes assessed via Wilcoxon two sample test and two sample T-test.
† Statistical significance assessed via the two sample T-test only.
** FET - Frozen Embryo Transfer.
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the time of data collection the live birth rates were simi-
lar for both gonadotrophins.
The results obtained in the current analysis are in
contrast to recent systematic reviews and meta-analyses
by Coomerasamy et al [9] (which included hMG as well
as hMG-HP) and Al-Inany et al [10] (which included
hMG-HP only) which reported no difference in average
comparative doses of rFSH and hMG-HP per IVF
(±ICSI) cycle. It should be noted that the doses of rFSH
used in many of the trials included in the systematic
review were higher than that routinely used in clinical
practice. For example, although the MERIT study [7]
showed that the average dose of rFSH was lower than
hMG-HP, it should be noted that the starting dose of
rFSH was 225 IU/day, which is higher than most clinics
outside of North America would administer [15]. The
mean starting dose in the current study was 176 IU/day
(± 50 IU) which is a 22% reduction on the mean starting
dose for rFSH in the MERIT study [7]. The more clini-
cally relevant median starting dose of treatment was
also significantly lower in the current study for rFSH
Table 5 Pregnancy outcomes - all patients
Characteristic rFSH hMG-HP Chi-square p-value
Total cycles started 22665 7965
Number (%) of total cycles with oocytes retrieved 22,467 (99.13%) 7,958 (99.91%) 54.73 <0.0001
Cycles (%) with positive pregnancy test as percent of cycles started 7595 (33.53%) 2553 (32.05) 5.72 0.0168
Cycles (%) with positive pregnancy test as percent of cycles with oocyte
retrieved
7595 (33.81% per ET) 2551 (32.06% per ET) 8.09 0.0044
Any clinical pregnancy as percent of cycles with oocyte retrieved 7423 (33.04) 2550 (32.04) 56.43 0.1037
Pregnancies ending in spontaneous abortion as percent of cycles with
oocyte retrieved
†
1303 (6.16%) 478 (6.02%) 0.19 0.6625
Note: Cycles with positive pregnancy test were defined as cycles with a biochemical pregnancy and any clinical pregnancy. Clinical pregnancies were defined
based on data entries ‘clinical pregnancy’, ‘ongoing pregnancy’, ‘live birth’,a n d‘spontaneous abortion’. Pregnancies ending in spontaneous abortion were
defined as those with data entries ‘spontaneous abortion’ and ‘miscarriage’.
† Due to lack of data on this outcome, only data for Germany and Denmark were
considered here to calculate the percentage (N = 21,160 for rFSH subgroup; N = 7,940 for hMG-HP subgroup).
Table 6 Pregnancy outcomes from the oocyte-retrieved cycles - age subgroups
Characteristic rFSH hMG-HP Chi-square p-value
Total cycles started
(≤35 years) 15422 5142
(≥36 years) 7243 2823
Number of total cycles with oocytes retrieved
(≤35 years) 15,293 (99.16%) 5,137 (99.90%) 32.55 <0.0001
(≥36 years) 7174 (99.05%) 2821 (99.93%) 22.55 <0.0001
Cycles with positive pregnancy test as percent of cycles started
(≤35 years) 5,440 (35.27%) 1,741 (33.86%) 3.40 0.0651
(≥36 years) 2157 (29.78%) 812 (28.76%) 1.01 0.3150
Cycles with positive pregnancy test as percent of cycles with oocyte retrieved
(≤35 years) 5,438 (35.56%) 1,739 (33.85%) 4.91 0.0267
(≥36 years) 2157 (30.07%) 812 (28.78%) 1.60 0.2065
Any clinical pregnancy with positive pregnancy test
(≤35 years) 5302 (97.50%) 1739 (100%) 44.33 <0.0001
(≥36 years) 2121 (98.33%) 811 (99.88%) 11.45 0.0007
Any clinical pregnancy as percent of cycles with oocyte retrieved
(≤35 years) 5302 (34.67%) 1739 (33.85%) 1.14 0.2864
(≥36 years) 2121 (29.57%) 811 (28.75%) 0.65 0.4197
Pregnancies ending in spontaneous abortion as percent of cycles with oocyte retrieved
†
(≤35 years) 860 (6.00%) 297 (5.79%) 0.30 0.5841
(≥36 years) 443 (6.48%) 181 (6.43%) 0.0071 0.9329
Note: Cycles with positive pregnancy test were defined as cycles with a biochemical pregnancy and any clinical pregnancy. Clinical pregnancies were defined
based on data entries ‘clinical pregnancy’, ‘ongoing pregnancy’, ‘live birth’,a n d‘spontaneous abortion’. Pregnancies ending in spontaneous abortion were
defined as those with data entries ‘spontaneous abortion’ and ‘miscarriage’.
† Due to lack of data on this outcome, only data for Germany and Denmark were considered here to calculate the percentage (N = 21,160 for rFSH subgroup;
N = 7,940 for hMG-HP subgroup).
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dose closely reflects that described in a recent article by
Trew (2007) [15].
Although conventional RCTs remain the “gold stan-
dard” for evidence-based medicine, observational data
reflects populations and settings that are more relevant
to clinical practice. The fact that this study used data
from a ‘real-world’ setting, suggests that the data pre-
sented herein represent a true reflection of the relative
amounts of gonadotrophin usage in clinical practice.
Also, this study included a large number of patients
with an excess of 30,000 IVF cycles; substantially larger
than clinical studies previously conducted in this area.
The results herein indicate that in everyday clinical
practice, a lower IU dose of rFSH can be used per IVF
(±ICSI) cycle, with clinical outcomes at least equivalent
to those for hMG-HP.
One implication of these study results is that the cost
of IVF treatment (±ICSI) with rFSH is likely to be sig-
nificantly less than is currently estimated. Current per-
ception is that equivalent doses of rFSH and hMG-HP
a r er e q u i r e d .T h ec u r r e n ts t u d yh a ss h o w nt h a tt h i si s
not the case in real-world practice and therefore, it is
possible that the higher unit cost of rFSH may be offset
by the lower dosage requirement versus hMG-HP.
T h er e s u l t so ft h ec u r r e n ts t u d ya l s oh a v ep o t e n t i a l
implications with regard to the recent HFEA policy on
single embryo transfer (SET) to minimise the risk of
multiple births from IVF [16]. Multiple births place a
significant health risk on both the mother (including a
higher risk of miscarriage and labour complications) and
the child (including a higher risk of neonatal mortality,
low birth rate, cerebral palsy and congenital abnormal-
ities) compared to singleton births. For this reason the
HFEA policy aims to reduce the UK IVF multiple birth
rate to 10% by 2012 over a staged period by administer-
ing SET to the most appropriate patients. A treatment
strategy that delivers a statistically higher number of
mature oocytes and embryos frozen per cycle may pro-
vide a more effective treatment strategy for patients sui-
table for SET and therefore should be the proposed
treatment of choice.
The observed absolute rates of hospitalisations due to
OHSS were generally low, and comparable to previous
reports [17]. However the incidence of both all OHSS
and hospitalisations due to OHSS were statistically
higher in cycles with rFSH than with hMG-HP. These
results are in contrast to previous studies comparing
rFSH with hMG-HP, including the MERIT study [7]
and a systematic review by Al-Inany et al [10] which
reported no significant difference in the rates of severe
OHSS between treatment groups. Logistic regression
analyses conducted as part of this study have demon-
strated that the type of gonadotrophin was not asso-
ciated with a higher risk of OHSS when adjusting for
the number of oocytes retrieved. It should be noted that
the current study differed from many randomised con-
trolled trials including the MERIT study in that patients
with polycystic ovary syndrome (PCO) were included in
the retrospective analysis whereas PCO was an exclusion
criterion for the MERIT study. PCO significantly
increases the risk of OHSS [18,19], and it is hypothe-
sised that an unequal distribution of PCO patients
between the two groups in this observational data set
may contribute in part to the higher rates of OHSS in
rFSH treated patients. Logistic regression analyses for
PCO were not possible because the cause of infertility
was not reported in the German dataset.
Patient characteristics should be considered before
choosing the GnRH analogue for down regulation and
tailoring the gonadotrophin dose to avoid excessive sti-
mulation. This could minimise the additional cost impli-
cations of treating OHSS.
Limitations of the study
As with all observational studies, this study is associated
with limitations including selection bias and confound-
ing factors [20]. Other limitations particular to this
study include generalisability of the data, differences in
how data and outcomes were reported across different
centres and countries, and local treatment regulations.
In this study, a significantly higher number of treat-
ment cycles were conducted with rFSH compared with
hMG-HP (74% of total cycles were with rFSH). However,
Table 7 Safety outcomes: OHSS
Characteristic Total rFSH hMG-hp Chi-square p-value
Number of cycles started* 28063 20144 7919
Cycles with OHSS (Severity I, II, III
and hospitalisation)
4928 (17.56%) 3812 (18.92%) 1116 (14.09%) 91.64 <0.0001
-Hospitalisation due to OHSS as
percent of cycles with OHSS
268 (5.44%) 215 (5.64% of cycles with OHSS) 53 (4.75% of cycles with OHSS) 1.33 0.2483
-Hospitalisation due to OHSS as
percent of cycles started
268 (0.95%) 215 (1.07% of cycles started) 53 (0.67% of cycles started) 9.52 0.002
*Due to lack of data on this outcome only data from Germany were included.
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group, the results remain statistically robust.
The majority of the data were obtained from a German
population, which means that the overall results will be
largely influenced by the German data set. Therefore, the
generalisability of the data for an EU population needs to
be carefully considered. There were differences in data
collection practices between different centres; the report-
ing of pregnancy outcomes differed between the partici-
pating centres, making the analysis of pregnancy
outcomes challenging and restricting the reporting of
some outcomes to one or more datasets. Also, in the
German dataset, IVF cycles where no oocytes were
retrieved were not included which explains why the pro-
portion of cycles with oocyte retrieval was so high
(>99%). It was not possible to quantify the cancellation
rate in Germany or to ascertain the reasons for treatment
failure within the German data set. Furthermore, due to
legal constraints in Germany and Switzerland, only three
embryos can be cultured per IVF cycle. This may result
in a smaller proportion of embryos being produced in
Germany and Switzerland when compared to other EU
countries where such constraints are not imposed, and
could have implications on the clinical pregnancy rate in
the fresh cycle. Furthermore in Germany and Switzer-
land, all embryos that survive until the embryo transfer
stage must be transferred to the uterus; this may have
implications on the multiple birth rate. In Denmark, elec-
tive single embryo transfer has become common practice
in recent years. This is unlikely to affect the overall clini-
cal pregnancy rate because the proportion of cycles from
Denmark was small in comparison to Germany.
Eligibility criteria proposed by NICE in their 2004
clinical guideline (CG11) were used to select IVF cycles
eligible for inclusion in this analysis. These criteria were
employed in the absence of consensus European guide-
lines. Although this may be viewed as a study limitation,
the IVF eligibility criteria in the four countries are com-
parable to those criteria suggested by NICE. The maxi-
mum age limits for IVF eligibility in each market are
similar to those in the NICE guideline; these range from
40-45 years, compared with a maximum age of 39 in
the NICE guideline, while in Switzerland, the median
age for fertility treatment is 36 years [21]. A maximum
BMI of 29 is defined in the NICE criteria, whereas there
are no official criteria regarding BMI limits in the
included markets, although the patient may be advised
to lose weight prior to IVF if obese. Reimbursement
practices differ between markets; however, three treat-
ment cycles are reimbursed in Germany and Denmark,
which is in line with NICE criteria.
The four EU countries included in this analysis had
readily available datasets, unlike the UK. A separate
retrospective observational chart review of UK centres is
currently underway.
The study included only cycles in which the starting
dose of gonadotrophin was ≤300 IU/day. This dosing
restriction, which was applied equally across both rFSH
and hMG-HP treatment groups, was included to capture
data from normal responders, thereby excluding poor
responders. It is however, possible that this has intro-
duced some bias into the study.
I ts h o u l da l s ob en o t e dt h a ti tw a sn o tp o s s i b l et o
attribute the number of hospitalisations to individual
grades of OHSS, due to the method of data collection in
Germany. However, given the size of the current study
the results presented herein are robust and reflect real-
world usage of gonadotrophins in IVF.
Conclusion
The current retrospective chart review, including patients
t h a tw o u l db ee l i g i b l ef o rI V Fu n d e rt h ec u r r e n tN I C E
guidelines, demonstrates that cycles with rFSH yield sta-
tistically more oocytes (and more mature oocytes), using
significantly less IU per cycle, versus hMG-HP. Clinical
pregnancy rates were comparable between treatment
groups with no evidence of higher rates of spontaneous
abortion. Of the started cycles, for which the final out-
come was known at the time of data collection, the live
birth rates were similar for both gonadotrophins. OHSS
requiring hospitalisation was low overall but significantly
higher in the rFSH group. The higher unit cost of rFSH
per 75 IU compared to the equivalent IU dose of the
Menopur brand of hMG-HP may be offset by the reduc-
tion of total IU dose required without a loss in efficacy
outcomes. The data generated from this ‘real-world’
study with its unprecedented cycle size is likely to yield
results that are more representative of everyday clinical
practice, compared to randomised clinical studies.
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